Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA Sep 22, 2022
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Sep 08, 2022
Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea Aug 30, 2022
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Aug 12, 2022
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Aug 11, 2022
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Aug 11, 2022
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation Aug 11, 2022
